Ruxolitinib + BAT

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera (PV)

Conditions

Polycythemia Vera (PV), Essential Thrombocythemia (ET)

Trial Timeline

Oct 1, 2015 → Dec 1, 2028

NCT ID

NCT02577926

About Ruxolitinib + BAT

Ruxolitinib + BAT is a phase 2 stage product being developed by Novartis for Polycythemia Vera (PV). The current trial status is active. This product is registered under clinical trial identifier NCT02577926. Target conditions include Polycythemia Vera (PV), Essential Thrombocythemia (ET).

What happened to similar drugs?

2 of 17 similar drugs in Polycythemia Vera (PV) were approved

Approved (2) Terminated (1) Active (15)

✅HydroxyureaNovartisApproved

✅Ropeginterferon alfa-2bPharmaEssentiaApproved

🔄Sapablursen + PlaceboOno PharmaceuticalPhase 3

🔄Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3

🔄ruxolitinib tabletsNovartisPhase 3

🔄RuxolitinibNovartisPhase 3

🔄Best Available Therapy + RuxolitinibNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02577926	Phase 2	Active	Oct 1, 2015	Dec 1, 2028	Polycythemia Vera (PV)

Competing Products

20 competing products in Polycythemia Vera (PV)

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	47
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Bomedemstat	Merck	Phase 2	35
Ruxolitinib + Hydroxycarbamide + Interferon-Alpha	Novartis	Phase 3	47
ruxolitinib tablets	Novartis	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ruxolitinib	Novartis	Phase 3	40
Hydroxyurea	Novartis	Approved	35
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	40
Smac Mimetic LCL161	Novartis	Phase 2	35
PEGASYS + Aspirin	Roche	Phase 2	35
RG7388 + Pegasys	Roche	Phase 1	29
Idasanutlin	Roche	Phase 2	27
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Phase 2	39
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	PharmaEssentia	Phase 3	40
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Approved	50
P1101 + Low-dose aspirin	PharmaEssentia	Phase 2	35
P1101 (Ropeginterferon alfa-2b)	PharmaEssentia	Phase 3	47